These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27986279)

  • 1. From CARs to TRUCKs and Beyond: Safely en Route to Adoptive T-cell Therapy for Cancer.
    Dummy
    EBioMedicine; 2016 Dec; 14():1-2. PubMed ID: 27986279
    [No Abstract]   [Full Text] [Related]  

  • 2. Chimeric antigen receptor T cell therapy: 25years in the making.
    Gill S; Maus MV; Porter DL
    Blood Rev; 2016 May; 30(3):157-67. PubMed ID: 26574053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regional Infusion of Chimeric Antigen Receptor T Cells to Overcome Barriers for Solid Tumor Immunotherapy.
    Hardaway JC; Prince E; Arepally A; Katz SC
    J Vasc Interv Radiol; 2018 Jul; 29(7):1017-1021.e1. PubMed ID: 29935783
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances in CAR T-cell therapy for chronic lymphocytic leukemia.
    Porter DL
    Clin Adv Hematol Oncol; 2018 Feb; 16(2):118-120. PubMed ID: 29741512
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
    Lu YC; Parker LL; Lu T; Zheng Z; Toomey MA; White DE; Yao X; Li YF; Robbins PF; Feldman SA; van der Bruggen P; Klebanoff CA; Goff SL; Sherry RM; Kammula US; Yang JC; Rosenberg SA
    J Clin Oncol; 2017 Oct; 35(29):3322-3329. PubMed ID: 28809608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.
    Srivastava S; Riddell SR
    J Immunol; 2018 Jan; 200(2):459-468. PubMed ID: 29311388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive T-cell therapy for cancer: The era of engineered T cells.
    Bonini C; Mondino A
    Eur J Immunol; 2015 Sep; 45(9):2457-69. PubMed ID: 26202766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.
    Feldman SA; Assadipour Y; Kriley I; Goff SL; Rosenberg SA
    Semin Oncol; 2015 Aug; 42(4):626-39. PubMed ID: 26320066
    [No Abstract]   [Full Text] [Related]  

  • 9. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.
    Houot R; Schultz LM; Marabelle A; Kohrt H
    Cancer Immunol Res; 2015 Oct; 3(10):1115-22. PubMed ID: 26438444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
    Holzinger A; Abken H
    Cancer Immunol Immunother; 2017 Nov; 66(11):1505-1507. PubMed ID: 28755091
    [No Abstract]   [Full Text] [Related]  

  • 11. New Strategies in Engineering T-cell Receptor Gene-Modified T cells to More Effectively Target Malignancies.
    Schmitt TM; Stromnes IM; Chapuis AG; Greenberg PD
    Clin Cancer Res; 2015 Dec; 21(23):5191-7. PubMed ID: 26463711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 'Off-the-shelf' immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes.
    Ando M; Nakauchi H
    Exp Hematol; 2017 Mar; 47():2-12. PubMed ID: 27826124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
    Michen S; Temme A
    Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer.
    Fix SM; Jazaeri AA; Hwu P
    Cancer Discov; 2021 Mar; 11(3):560-574. PubMed ID: 33563662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses.
    Chicaybam L; Bonamino MH
    Int Rev Immunol; 2014 Oct; 33(5):402-16. PubMed ID: 24911925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 17. The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.
    Orlowski RJ; Porter DL; Frey NV
    Br J Haematol; 2017 Apr; 177(1):13-26. PubMed ID: 27977050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigen choice in adoptive T-cell therapy of cancer.
    Offringa R
    Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moving from tinkering in the garage to assembly line production: the manufacture of genetically modified T cells expressing chimeric antigen receptors (CARs) comes on line.
    Cooper LJ
    Cancer Gene Ther; 2015 Mar; 22(2):64-6. PubMed ID: 25675874
    [No Abstract]   [Full Text] [Related]  

  • 20. TCR-engineered T cells to treat tumors: Seeing but not touching?
    Debets R; Donnadieu E; Chouaib S; Coukos G
    Semin Immunol; 2016 Feb; 28(1):10-21. PubMed ID: 26997556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.